273 related articles for article (PubMed ID: 28432050)
1. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.
Mok CC; Ho LY; Tse SM; Chan KL
Ann Rheum Dis; 2017 Aug; 76(8):1420-1425. PubMed ID: 28432050
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Groot N; Shaikhani D; Teng YKO; de Leeuw K; Bijl M; Dolhain RJEM; Zirkzee E; Fritsch-Stork R; Bultink IEM; Kamphuis S
Arthritis Rheumatol; 2019 Feb; 71(2):290-301. PubMed ID: 30152151
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
4. Does hydroxychloroquine improve patient reported outcomes in patients with lupus?
Jolly M; Sehgal V; Arora S; Azizoddin D; Pinto B; Sharma A; Devilliers H; Inoue M; Toloza S; Bertoli A; Blazevic I; Vilá LM; Moldovan I; Torralba KD; Mazzoni D; Cicognani E; Hasni S; Goker B; Haznedaroglu S; Bourre-Tessier J; Navarra SV; Clarke A; Weisman M; Wallace D; Mok CC
Lupus; 2021 Oct; 30(11):1790-1798. PubMed ID: 34304629
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Clin Rheumatol; 2019 Oct; 38(10):2785-2791. PubMed ID: 31175481
[TBL] [Abstract][Full Text] [Related]
7. A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis.
Shaharir SS; Ghafor AH; Said MS; Kong NC
Lupus; 2014 Apr; 23(4):436-42. PubMed ID: 24399814
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
Petri M; Magder LS
Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
[TBL] [Abstract][Full Text] [Related]
9. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
[TBL] [Abstract][Full Text] [Related]
10. Systemic Lupus Erythematosus: A Review.
Siegel CH; Sammaritano LR
JAMA; 2024 May; 331(17):1480-1491. PubMed ID: 38587826
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
Intern Med; 2019 May; 58(9):1257-1262. PubMed ID: 30626831
[TBL] [Abstract][Full Text] [Related]
13. Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.
Salgado Guerrero M; Londono Jimenez A; Dobrowolski C; Mowrey WB; Goilav B; Wang S; Broder A
BMC Nephrol; 2020 Oct; 21(1):450. PubMed ID: 33115441
[TBL] [Abstract][Full Text] [Related]
14. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
[TBL] [Abstract][Full Text] [Related]
15. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
[TBL] [Abstract][Full Text] [Related]
16. Prolonged clinical remission and low disease activity statuses are associated with better quality of life in systemic lupus erythematosus.
Poomsalood N; Narongroeknawin P; Chaiamnuay S; Asavatanabodee P; Pakchotanon R
Lupus; 2019 Sep; 28(10):1189-1196. PubMed ID: 31307256
[TBL] [Abstract][Full Text] [Related]
17. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes.
Zen M; Iaccarino L; Gatto M; Bettio S; Nalotto L; Ghirardello A; Punzi L; Doria A
Ann Rheum Dis; 2015 Dec; 74(12):2117-22. PubMed ID: 26223434
[TBL] [Abstract][Full Text] [Related]
18. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
Iudici M; Pantano I; Fasano S; Pierro L; Charlier B; Pingeon M; Dal Piaz F; Filippelli A; Izzo V
Lupus; 2018 Feb; 27(2):265-272. PubMed ID: 28659047
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia.
Seo MR; Chae J; Kim YM; Cha HS; Choi SJ; Oh S; Roh CR
Lupus; 2019 May; 28(6):722-730. PubMed ID: 30971164
[TBL] [Abstract][Full Text] [Related]
20. Risk of osteonecrosis in systemic lupus erythematosus: An 11-year Chinese single-center cohort study.
Long Y; Zhang S; Zhao J; You H; Zhang L; Li J; Leng X; Wang Q; Tian X; Li M; Zeng X
Lupus; 2021 Aug; 30(9):1459-1468. PubMed ID: 34082592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
